AstraZeneca offloaded former Amgen-partnered IL-17 antagonist brodalumab to Valeant; there was consolidation in the dental instruments industry via the $5.3bn merger of Dentsply and Sirona. Compared with August, financing in the biopharma sector was up while device was flat.

Start-ups raised $2.57 billion in Q3. Biopharma companies penned 23 alliances; 11 acquisitions were signed, none in the diagnostics industry.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Tools – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2015.